Better Therapeutics, Inc. · OTC:BTTX
Better Therapeutics — Investor Presentation (November 2021)
28 slides from Better Therapeutics's investor presentation, Nov 18, 2021
Slide 1: Company Presentation | November 2021
Exhibit 99.2 COMPANY PRESENTATION | NOVEMBER 2021
Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the Company“) nor any of its respective affiliates nor any of its or their control persons, off
Slide 3: Recent Progress
Pivotal trial of BT-001 (type 2 diabetes) is fully enrolled; primary endpoint Q1 2022 BT-002 (hypertension) pivotal trial expected to begin in 2022 Early clinical discovery in non-alcoholic fatty liver Recent disease (NAFLD) to enroll 1st patient in Q1 2022 Progress Real-world evidence study enrolle
Slide 4: Executive Team
Executive Team David Kevin Mark Justin Mark Kristin Thiago Deepti Jaggi, Perry Appelbaum Berman, MD Zamirowski Heinen Wynholds Oliveira PharmD Co-Founder, Co-Founder, Chief Chief Medical Chief Commercial Interim Chief Chief Product Chief People Chief Strategy Chairman Executive Officer Officer Offic
Slide 5: Next Generation Therapeutics: Using Software Instead of Drugs
Next Generation Therapeutics: Using Software Instead of Drugs A Digital Therapeutics Platform – delivering novel cognitive behavioral therapy targeting the root causes of cardiometabolic diseases Demonstrated Results– clinically meaningful results in multiple trials for Type 2 Diabetes and Hypertens
Slide 6: We are spending more and more money to get worse and worse outcomes
We are spending more and more money to get worse and worse outcomes DIABETES HYPERTENSION US Healthcare Expenditures ($ in trillions) Americans Diagnosed with Hypertension (millions) US Healthcare Expenditures ($ in trillions) Americans Diagnosed with Diabetes (millions) $4 30 $4 110 $3 $3 22.5 82.5
Slide 7: Existing therapeutics treat symptoms but leave the common root causes untouched
Hypertension (high blood pressure) 70M people $30B Rx drug spending That’s because Type 2 Diabetes (high blood sugar) Root Causes existing therapeutics 35M people Poor diet $52B Rx drug spending Sedentary lifestyle treat symptoms but Stress Poor sleep leave the common Alcohol, Tobacco root causes un
Slide 8: CBT is effective but neither scalable nor affordable
Cognitive Behavioral Therapy (CBT) is effective at addressing the behavioral root causes of cardiometabolic diseases but is neither scalable nor affordable Treatment plans to treat cardio metabolic “The results of this study show that PC-CBT lifestyle intervention [for patients diseases with CBT are
Slide 9: Founded on the hypothesis that software could change patient behavior
Better Therapeutics was founded on the hypothesis that we could create software that would change patient behavior and treat underlying causes of cardiometabolic diseases; and deliver it in a scalable and affordable mobile application 9
Slide 10: FDA de novo pathway for software as a treatment
Our first submission will be a de novo In 2017, the FDA classification request established a Subsequent submissions may be 510(k)s pathway for the approval of software Pear Therapeutics, Akili Interactive, Mahana as a treatment Therapeutics have received authorization or clearance via this approach
Slide 11: Patients and providers are interested in alternatives addressing underlying causes
Both patients and healthcare providers are highly interested in treatment alternatives that address the underlying causes of disease Provider Qualitative Research Results (n=30) 80% rate it a 6 or 7 Provider Average 7% 14% 28% 52% 6.2 / 7 1 2 3 4 5 6 7 Patient Qualitative Research Results (n=20) 69%
Slide 12: Payer research supports our coverage and reimbursement assumptions
Payer research supports our coverage and reimbursement assumptions $1,000 High Risk $900 At this price range, payers will likely attempt to strictly • • Blinded interviews conducted with 17 key manage BT-001 beyond label >$600 decision-makers in Commercial and $800 Not covered, Medical Exception onl
Slide 13: Now is a unique time to build a valuable prescription digital therapeutics company
Now is a unique time to build a very valuable prescription digital therapeutics company We can’t continue to pay more money for worse outcomes CBT is well established to treat the underlying causes of these diseases Our software platform has demonstrated clinically meaningful results in multiple tri
Slide 14: Software platform delivering nutritional CBT
We have created a software platform that delivers nutritional CBT and it has demonstrated clinically meaningful results in multiple trials NEUROSCIENCE LIFESTYLE MEDICINE ARTIFICIAL INTELLIGENCE Behavior Therapy Treatment Plans Personalization Changes thoughts and A pre-programmed beliefs so that di
Slide 15: Pilot study in patients with type 2 diabetes
In our most recent pilot study in patients with type 2 diabetes, we observed that use of our software generated results similar to prescription drugs with few side effects Change in Fasting Blood Glucose Clinical Observations 1 (n = 80, enrolled with baseline A1c 7.0 to 11.0%) Greater than expected
Slide 16: Pivotal Trial - BT-001
*PIVOTAL TRIAL - BT-001 A pivotal trial of our product for treating type 2 diabetes is underway; we expect primary data in Q1 2022 and an FDA submission in mid 2022 First Patient First Patient Primary Endpoint Last Patient Interim Analysis Screened Randomized Data Out Feb-21 Apr-21 Dec-21 Q1-22 Q2-2
Slide 17: Pipeline development faster and at less cost than traditional therapeutics
We believe we can develop this pipeline faster and at less cost than traditional therapeutics, allowing us to scale much more quickly Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Pivotal FDA Review Type 2 Diabetes Pilot Pivotal Hyperlipidemia Pivota
Slide 18: Current treatment paradigm: symptoms worsen and costs increase
In the current treatment paradigm, disease symptoms worsen and healthcare costs increase for the remainder of life Progression of Disease Additional Non-Insulin Advanced Pre-Diabetes / Insulin Non-Insulin Diagnosis Treatment Comorbidities At-Risk Stage Treatment Treatments +3.2x +1.8x drug cost / dr
Slide 19: A new paradigm: disease progression stops and is reversed
By treating the underlying causes of disease, we make a new paradigm possible; one in which disease progression stops and in many patients is reversed Progression of Disease Pre-Diabetes / Diagnosis At-Risk Stage Additional Non-Insulin Non-Insulin Treatment Treatments Advanced Insulin Comorbidities
Slide 20: Over $40B of addressable drug spending in diabetes
In diabetes alone, there is over $40B of addressable drug spending on insured patients with uncontrolled diabetes 12M 73% $4,500 = $40B Patients with Covered by Annual diabetes drug Immediate uncontrolled diabetes Commercial Payers costs per patient Addressable Market and A1c 7-11% or Medicare Part
Slide 21: Diabetes drug spending expected to grow 2.5x over the next 10 years
Diabetes drug spending is expected to grow by 2.5x over the next 10 years, but our approach could begin to reduce the cost of treating diabetes and almost every other metabolic disease $120 $105B $93B $90 $60 $40B $30 $15B $0 2010 2020 2030 2030 w/BT-001 authorized Yesterday Today Tomorrow 21
Slide 22: Aligned with Existing Clinical Guidelines
Aligned with Existing Clinical Guidelines By choosing to seek Physician examines patient FDA approval for our products, we seek to Physician diagnoses patient fit seamlessly within the existing Physician prescribes therapy healthcare system to Payer reimburses like a drug enable adoption and scale,
Slide 23: 4% of Primary Care Providers Treat 20% of Patients
4% of Primary Care Providers Treat 20% of Patients 86% of type 2 23,000,000 388,717 diabetes patient care 224,364 (pre insulin) is 162,082 17,250,000 delivered by primary 121,206 90,558 care providers. 11,500,000 66,249 46,468 A small portion of 23,592 5,750,000 providers care for a 16,998 6,636 dis
Slide 24: Commercial Team Composition
Commercial Team Composition Sizing at FDA Annualized Role Focus Authorization Cost We plan to build a Health System formulary acceptance and Engagement and digital first engagement and education for ~20 $8M Education providers and patients commercial capability KOL engagement, real world study to la
Slide 25: BT-001 expected to improve outcomes and save payers money
BT-001 is expected to both improve patient outcomes and save payers money 3-year Cost Clinical Impact Branded Drug Cost (Wholesale) (A1c Reduction) (30 day wholesale cost) Trulicity (GLP-1 RA Inj.) Trulicity (GLP-1 RA Inj.) Trulicity (GLP-1 RA Inj.) 1.7% $797 $21,336 Rybelsus (GLP-1 RA Oral) Rybelsu
Slide 26: 1,000 participant real-world evidence study
We have begun enrolling a 1,000 participant real-world evidence (RWE) study to understand BT-001 durability of effect and impact on total cost of care 6-Month Data 9-Month Data 9-Month Data Last Patient In First Patient In (250 pts) (750 pts) (1000 pts) Q4-23 Oct-21 Q3-22 Q4-22 Q2-23 BT-001 Study Si
Slide 27: Opportunity to create a valuable company based on diabetes revenues alone
We have the opportunity to create a valuable company based on diabetes revenues alone Gross Profit EBIT Revenues $400 $400 $35 $390 $16 $0 -$30 -$44 -$117 -$132 $300 $300 $310 -$35 $200 $200 -$70 $100 $100 $88 -$105 $63 $0 $0 $0 $7 $0 $0 -$140 2021 2023 (Launch Year) 2025 2021 2022 2023 2024 2025 202
Slide 28: Multiple value creation milestones over the next 8 months
We expect multiple value creation milestones over the next 18 months Enrollment Pivotal Trial Pivotal Trial Pilot Data Complete First Patient In First Patient In [BT-002, -003] [BT-001] [BT-002] [BT-003] Secondary Endpoint FDA Interim [BT-001] FDA Authorization Primary Endpoint Close SPAC Submission
Better Therapeutics — Investor Presentation (November 2021) on 6ix